Intercept Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$152.1M
Doctors Paid
17,716
Transactions
103,839
2024 Total
$5.1M
Payment Breakdown by Category
Research$130.7M (85.9%)
Consulting$9.1M (6.0%)
Food & Beverage$1.9M (1.3%)
Travel$899,102 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $130.7M | 22,319 | 85.9% |
| Consulting Fee | $9.1M | 2,385 | 6.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3.1M | 1,204 | 2.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2.8M | 990 | 1.9% |
| Honoraria | $2.6M | 1,705 | 1.7% |
| Food and Beverage | $1.9M | 72,301 | 1.3% |
| Travel and Lodging | $899,102 | 2,504 | 0.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $638,025 | 21 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $209,900 | 42 | 0.1% |
| Grant | $97,300 | 21 | 0.1% |
| Education | $44,891 | 347 | 0.0% |
Payments by Type
Research
$130.7M
22,307 transactions
General
$21.4M
81,520 transactions
Ownership
$0
12 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| 1009742 | $33.8M | 3 | 4,465 |
| 1011866 | $33.3M | 4 | 5,423 |
| Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | $21.6M | 19 | 5,093 |
| Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) | $18.0M | 4 | 3,313 |
| 303 | $10.0M | 0 | 1,749 |
| 1010016 | $2.1M | 0 | 238 |
| General Research - Contracts | $1.6M | 0 | 15 |
| PBC FOLD | $1.4M | 0 | 4 |
| Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | $1.2M | 0 | 371 |
| A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis | $1.2M | 0 | 202 |
| The Progression and Natural History of Pediatric Nonalcoholic Fatty Liver Disease | $998,944 | 0 | 16 |
| 1011507 | $887,523 | 0 | 383 |
| Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT) | $848,136 | 6 | 260 |
| 209 | $545,601 | 0 | 106 |
| 207 | $536,766 | 0 | 145 |
| Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC | $486,670 | 4 | 74 |
| 1011386 | $360,126 | 0 | 99 |
| 302 | $316,892 | 0 | 104 |
| A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis | $222,842 | 0 | 8 |
| 7001735 | $211,818 | 0 | 41 |
| 301 | $183,112 | 0 | 34 |
| A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | $178,298 | 0 | 17 |
| Study of OCA Evaluating Pharmacokinetics and Safety in Patients With PBC and Hepatic Impairment | $149,175 | 1 | 47 |
| 1012528 | $130,437 | 0 | 24 |
| A Study of INT-747 6-ECDCA Monotherapy in Patients With Primary Biliary Cirrhosis NCT00570765 | $116,013 | 0 | 18 |
| A Phase 3,Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis | $106,346 | 0 | 3 |
| 747-207 | $93,957 | 0 | 11 |
| Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis REVERSE | $81,786 | 0 | 15 |
| A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis with Fibrosis | $34,252 | 0 | 2 |
| Phase 2 Study on Effects of Obeticholic Acid OCA on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis | $26,370 | 0 | 17 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Haytham Elgammal | Surgery | Miami, FL | $2.2M | $0 |
| Keith Gottesdiener, M.d, M.D | Infectious Disease | Rahway, NJ | $671,705 | $0 |
| Robert Gish, M.d, M.D | Gastroenterology | Folsom, CA | $434,325 | $0 |
| Dr. Christopher Wohlberg, Md, Phd, MD, PHD | Neurology | Allentown, PA | $348,275 | $0 |
| Kris Kowdley, Md, MD | Gastroenterology | Seattle, WA | $348,052 | $0 |
| Dr. Loren Laine, M.d, M.D | Gastroenterology | West Haven, CT | $344,830 | $0 |
| Chakradhar Reddy, M.d, M.D | Transplant Hepatology | Johnson City, TN | $342,340 | $0 |
| Dr. Harvey Schneier, M.d, M.D | Internal Medicine | New York, NY | $334,119 | $0 |
| Lance Stein, Md, MD | Transplant Hepatology | Atlanta, GA | $304,416 | $0 |
| Sonal Kumar, Md, MD | Gastroenterology | New York, NY | $264,459 | $0 |
| Jeffrey Williams, Md, MD | Gastroenterology | Athens, GA | $254,753 | $0 |
| Joseph Konen, Md, MD | Family Medicine | Charlotte, NC | $232,256 | $0 |
| Adam Peyton, Do, DO | Gastroenterology | Allentown, PA | $228,743 | $0 |
| Dr. Julio Gutierrez, Md, MD | Internal Medicine | Los Angeles, CA | $224,661 | $0 |
| Michael Kochman, Md, MD | Internal Medicine | Philadelphia, PA | $200,197 | $0 |
| Zobair Younossi, Md, MD | Surgery | Falls Church, VA | $199,462 | $0 |
| Dr. Martin Moehlen, M.d, M.D | Internal Medicine | Portland, ME | $196,898 | $0 |
| Dr. Robert Brown, Md, MD | Hepatology | New York, NY | $194,334 | $0 |
| Naim Alkhouri, Md, MD | Internal Medicine | Westlake, OH | $192,299 | $0 |
| Steven Flamm, Md, MD | Gastroenterology | Chicago, IL | $184,008 | $0 |
| Rohit Loomba, Md, MD | Internal Medicine | La Jolla, CA | $178,734 | $0 |
| James Freston, M.d, M.D | Gastroenterology | Farmington, CT | $174,100 | $0 |
| Dr. Jules Dienstag, Md, MD | Internal Medicine | Boston, MA | $165,150 | $0 |
| Dr. Mitchell Shiffman, Md, MD | Gastroenterology | Newport News, VA | $158,932 | $0 |
| Unknown Provider | — | — | $155,800 | $0 |
Ad
Top Products
- OCALIVA $81.3M
- OCA $6.1M
Associated Products (3)
- OCALIVA $91.2M
- OCA $6.1M
- OBETICHOLIC ACID $155,088
Payment Categories
- Food & Beverage $1.9M
- Consulting $9.1M
- Travel & Lodging $899,102
- Research $130.7M
About Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc. has made $152.1M in payments to 17,716 healthcare providers, recorded across 103,839 transactions in the CMS Open Payments database. In 2024, the company paid $5.1M. The top product by payment volume is OCALIVA ($81.3M).
Payments were distributed across 156 medical specialties. The top specialty by payment amount is Gastroenterology ($7.7M to 6,471 doctors).
Payment categories include: Food & Beverage ($1.9M), Consulting ($9.1M), Research ($130.7M), Travel & Lodging ($899,102).
Intercept Pharmaceuticals, Inc. is associated with 3 products in the CMS Open Payments database.